# US 11,998,569 B2 · Method of transporting mesenchymal stem cells by means of a transporting solution and a method of administering stem cells to wounds > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,998,569 B2 - Document ID: US11998569B2 - Status: Granted - Kind: B2 - Application number: 17/816,515 - Filed: 2022-08-01 - Published: 2023-02-16 - Granted: 2024-06-04 - Earliest claimed: 2018-04-09 - Assignees: Cellresearch Corporation Pte. Ltd. - Applicants: Cellresearch Corporation Pte. Ltd. - Inventors: Toan Thang Phan; Brian M. Freed - Web page: https://patentgrep.com/patent/US11998569B2 ## CPC - A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells - A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)} - A61K 9/10: Dispersions; Emulsions - A61K 47/46: Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts - A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like - C12N 5/0018: {Culture media for cell or tissue culture (media for specific animal cell type C12N5/06)} - C12N 5/0605: {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly} - C12N 5/0663: {Bone marrow mesenchymal stem cells (BM-MSC)} - C12N 2500/10: Metals; Metal chelators - C12N 2500/32: Amino acids - C12N 2500/34: Sugars - C12N 2500/38: Vitamins - C12N 2500/40: Nucleotides, nucleosides or bases - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract The present invention relates to a method of transporting a stem cell population, the method comprising transporting the stem cell population contacted with a liquid carrier. In addition, the present invention concerns a method of treating a subject having a disease, the method comprising topically administering a defined mesenchymal stem cell population to the subject, wherein the mesenchymal stem cell population is administered within about 96 hours from the time point the mesenchymal stem cell population has been harvested. Also concerned is a unit dosage comprising about 20 million cells, of about 15 million cells, of about 10 million cells, of about 5 million cells, of about 4 million cells, of about 3 million cells, of about 2 million cells, of about 1 million cells, of about 0.5 million cells, of about 0.25 million cells or of less than 0.25 million cells of a defined mesenchymal stem cell population. ## Claims ### Claim 1 A unit dosage of a mesenchymal stem cell population, wherein the mesenchymal stem cell population is an isolated mesenchymal stem population of the amniotic membrane of the umbilical cord, wherein at least 97% or more of the cells of the isolated mesenchymal stem cell population express each of CD73, CD90 and CD105 and lack expression of each of CD34, CD45 and HLA-DR and wherein the unit dosage comprise about 0.5 million cells to about 20 million cells contained in a liquid carrier, wherein the liquid carrier comprises i) Trolox; ii) Na+; iii) K+; iv) Cl−; v) H2PO4-; vi) HEPES; vii) Lactobionate; viii) Sucrose; ix) Mannitol; x) Glucose; xi) Dextran-40; xii) Adenosine, and xiii) Glutathione. ### Claim 2 (depends on 1) The unit dosage of claim 1, wherein the unit dose comprises about 15 million cells, about 10 million cells, about 9 million cells, about 8 million cells, about 7 million cells, about 6 million cells, about 5 million cells, about 4 million cells, about 3 million cells, about 2 million cells, or about 1 million cells of the mesenchymal stem cell population. ### Claim 3 (depends on 1) The unit dosage of claim 1, wherein the unit dosage comprises about 10 million cells. ### Claim 4 (depends on 1) The unit dosage of claim 1, wherein the unit dosage is contained in a 1 ml vial. ### Claim 5 (depends on 1) The unit dosage of claim 1, wherein the cells are viable cells. ### Claim 6 (depends on 1) The unit dosage of claim 1, wherein the unit dose is contained in a volume 1 ml of the liquid carrier. ### Claim 7 (depends on 1) The unit dosage of claim 1, wherein the unit dosage comprises about 15 million cells. ### Claim 8 (depends on 1) The unit dosage of claim 1, wherein the unit dosage comprises about 9 million cells. ### Claim 9 (depends on 1) The unit dosage of claim 1, wherein the unit dosage comprises about 8 million cells. ### Claim 10 (depends on 1) The unit dosage of claim 1, wherein the unit dosage comprises about 7 million cells. ### Claim 11 (depends on 1) The unit dosage of claim 1, wherein the unit dosage comprises about 6 million cells. ### Claim 12 (depends on 1) The unit dosage of claim 1, wherein the unit dosage comprises about 5 million cells. ### Claim 13 (depends on 1) The unit dosage of claim 1, wherein the unit dosage comprises about 4 million cells. ### Claim 14 (depends on 1) The unit dosage of claim 1, wherein the unit dosage comprises about 3 million cells. ### Claim 15 (depends on 1) The unit dosage of claim 1, wherein the unit dosage comprises about 2 million cells. ### Claim 16 (depends on 1) The unit dosage of claim 1, wherein the unit dosage comprises about 1 million cells. ### Claim 17 (depends on 1) The unit dosage of claim 1, wherein at least 97% or more of the cells of the isolated mesenchymal stem cell population express POU5f1. ### Claim 18 (depends on 6) The unit dosage of claim 6, wherein at least 97% or more of the cells of the isolated mesenchymal stem cell population express POU5f1.